No próximo dia 8 de dezembro de 2017, no primeiro dia do 28º Simpósio Internacional de DNM/ELA, será realizada uma importante sessão voltada à apresentação e discussão de vários ensaios clínicos na DNM/ELA com diversas drogas que atualmente estão em fase de pesquisa, conforme programa abaixo:
Boston, USA 8-10 December 2017
Day One
Session 4B: 16.00 - 17.45
CLINICAL
TRIALS
|
|
16.00 – 16.20
|
Masitinib as an add-on therapy to riluzole is safe
and effectivein the
treatment of ALS
J S Mora (Spain)
|
16.20 – 16.40
|
VITALITY-ALS: Results
of a phase 3 trial of tirasemtiv, a
fast skeletal
muscle troponin activator, as a potential treatment
for patients with ALS
J Shefner (USA)
|
16.40 – 16.55
|
Efficacy, safety
and tolerability study of 1mg rasagiline
in ALS:
A prospective, randomized, parallel-group, double-blind
trial
A Ludolph (Germany)
|
16.55 – 17.10
|
Ibudilast: Bi-modal therapy with riluzole in early
and advanced ALS
patients
B Brooks (USA)
|
17.10 – 17.25
|
Towards more
efficient clinical trial designs in ALS: Lessons from the
Edaravone Development Programme
J
Palumbo (USA)
|
17.25 - 17.45
|
Discussion
|
Fonte: https://www.mndassociation.org/symposium/for-presenters/for-oral-presenters/
